SL
KLRS

Siren LLC’s Kalaris Therapeutics KLRS Stock Holding History

Siren LLC’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.51M Hold
435,798
– – 0.07% 87
2025
Q4 		$3.68M Buy
435,798
+117,534
+37% +$752K 0.11% 89
2025
Q3 		$1.84M Buy
318,264
+35,678
+13% +$118K 0.07% 91
2025
Q2 		$755K Hold
282,586
– – 0.04% 99
2025
Q1 		$2.27M Sell
282,586
-4,247
-1% -$41.6K 0.13% 81
2024
Q4 		$2.77M Hold
286,833
– – 0.12% 83
2024
Q3 		$5.33M Buy
+286,833
New +$5.02M 0.27% 66

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Siren LLC's KLRS Position: Q1 2026 in Review

Siren LLC held its Kalaris Therapeutics (KLRS) position steady in Q1 2026 at 435,798 shares worth $2.51M. The position accounts for 0.07% of the portfolio, ranked #87.

Siren LLC first reported a position in KLRS in Q3 2024 and has held it in 7 quarters since. The position peaked at $5.33M in Q3 2024. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Siren LLC held 435,798 shares of Kalaris Therapeutics worth $2.51M as of Q1 2026.
  • Siren LLC left its Kalaris Therapeutics share count unchanged in Q1 2026.
  • Kalaris Therapeutics made up 0.07% of Siren LLC's portfolio in Q1 2026, its #87 holding.
  • Siren LLC first reported a position in Kalaris Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Siren LLC's Kalaris Therapeutics position peaked at $5.33M in Q3 2024.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Siren LLC's 13F filing for Q1 2026, filed 14 May 2026.